This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-128-3p | A2M | 0.78 | 0 | -0.31 | 0.00047 | miRNAWalker2 validate | -0.17 | 0 | NA | |
2 | hsa-miR-128-3p | ABCA1 | 0.78 | 0 | 0.02 | 0.83411 | MirTarget | -0.17 | 0 | NA | |
3 | hsa-miR-128-3p | ARID3B | 0.78 | 0 | -0.1 | 0.03142 | MirTarget | -0.11 | 0 | NA | |
4 | hsa-miR-128-3p | ARRDC4 | 0.78 | 0 | -0.19 | 0.01538 | MirTarget | -0.15 | 0 | NA | |
5 | hsa-miR-128-3p | B4GALT1 | 0.78 | 0 | -0.15 | 0.04686 | miRNAWalker2 validate | -0.17 | 0 | NA | |
6 | hsa-miR-128-3p | BMF | 0.78 | 0 | -0.43 | 1.0E-5 | MirTarget | -0.39 | 0 | NA | |
7 | hsa-miR-128-3p | BOC | 0.78 | 0 | -0.23 | 0.00885 | miRNAWalker2 validate | -0.13 | 1.0E-5 | NA | |
8 | hsa-miR-128-3p | BRCA2 | 0.78 | 0 | -1.03 | 0 | miRNAWalker2 validate | -0.34 | 0 | NA | |
9 | hsa-miR-128-3p | CASP3 | 0.78 | 0 | -0.26 | 0 | miRNAWalker2 validate | -0.15 | 0 | NA | |
10 | hsa-miR-128-3p | CCL18 | 0.78 | 0 | 0.25 | 0.29925 | MirTarget | -0.44 | 0 | NA | |
11 | hsa-miR-128-3p | CD276 | 0.78 | 0 | -0.46 | 0 | MirTarget | -0.3 | 0 | NA | |
12 | hsa-miR-128-3p | CD2AP | 0.78 | 0 | -0.15 | 0.00191 | miRNAWalker2 validate | -0.12 | 0 | NA | |
13 | hsa-miR-128-3p | CD300A | 0.78 | 0 | -0.35 | 0.00049 | miRNAWalker2 validate | -0.27 | 0 | NA | |
14 | hsa-miR-128-3p | CDCP1 | 0.78 | 0 | -0.51 | 1.0E-5 | MirTarget | -0.31 | 0 | NA | |
15 | hsa-miR-128-3p | CDKN2A | 0.78 | 0 | -0.02 | 0.90392 | MirTarget | -0.26 | 1.0E-5 | NA | |
16 | hsa-miR-128-3p | CLIC4 | 0.78 | 0 | -0.32 | 4.0E-5 | MirTarget | -0.22 | 0 | NA | |
17 | hsa-miR-128-3p | CLP1 | 0.78 | 0 | -0.18 | 0 | MirTarget | -0.12 | 0 | NA | |
18 | hsa-miR-128-3p | CLPP | 0.78 | 0 | -0.17 | 0.00059 | miRNAWalker2 validate; MirTarget | -0.17 | 0 | NA | |
19 | hsa-miR-128-3p | CLSPN | 0.78 | 0 | -1.31 | 0 | miRNAWalker2 validate | -0.16 | 0.00691 | NA | |
20 | hsa-miR-128-3p | CMTM6 | 0.78 | 0 | -0.33 | 0 | miRNAWalker2 validate | -0.19 | 0 | NA | |
21 | hsa-miR-128-3p | COL3A1 | 0.78 | 0 | -1.43 | 0 | MirTarget | -0.7 | 0 | NA | |
22 | hsa-miR-128-3p | CREB3L2 | 0.78 | 0 | -0.2 | 0.00053 | MirTarget | -0.15 | 0 | NA | |
23 | hsa-miR-128-3p | CSF1 | 0.78 | 0 | 0.12 | 0.20838 | MirTarget | -0.13 | 8.0E-5 | 22909061 | By mutations in putative miRNA targets in CSF-1 mRNA 3'UTR we identified a common target for both miR-128 and miR-152; We have also found that both miR-128 and miR-152 down-regulate CSF-1 mRNA and protein expression in ovarian cancer cells leading to decreased cell motility and adhesion in vitro two major aspects of the metastatic potential of cancer cells; Our results provide the evidence for a mechanism by which miR-128 and miR-152 down-regulate CSF-1 an important regulator of ovarian cancer |
24 | hsa-miR-128-3p | CTDSP1 | 0.78 | 0 | -0.05 | 0.33671 | miRNAWalker2 validate | -0.16 | 0 | NA | |
25 | hsa-miR-128-3p | CTDSP2 | 0.78 | 0 | -0.23 | 0.00019 | MirTarget | -0.13 | 0 | NA | |
26 | hsa-miR-128-3p | CTSZ | 0.78 | 0 | -0.25 | 0.00512 | miRNAWalker2 validate | -0.17 | 0 | NA | |
27 | hsa-miR-128-3p | CTU1 | 0.78 | 0 | -0.1 | 0.10104 | MirTarget | -0.13 | 0 | NA | |
28 | hsa-miR-128-3p | DOCK11 | 0.78 | 0 | -0.34 | 0 | MirTarget | -0.18 | 0 | NA | |
29 | hsa-miR-128-3p | DOT1L | 0.78 | 0 | -0.2 | 0.00987 | MirTarget | -0.2 | 0 | NA | |
30 | hsa-miR-128-3p | E2F7 | 0.78 | 0 | -1.47 | 0 | miRNAWalker2 validate | -0.48 | 0 | NA | |
31 | hsa-miR-128-3p | ECE1 | 0.78 | 0 | -0.45 | 0 | MirTarget | -0.17 | 0 | NA | |
32 | hsa-miR-128-3p | EFEMP2 | 0.78 | 0 | -0.47 | 7.0E-5 | miRNAWalker2 validate | -0.14 | 0.00101 | NA | |
33 | hsa-miR-128-3p | EGFR | 0.78 | 0 | -0.38 | 0.01555 | miRNAWalker2 validate; miRTarBase | -0.12 | 0.02954 | NA | |
34 | hsa-miR-128-3p | ERCC1 | 0.78 | 0 | -0.15 | 0.00613 | MirTarget | -0.12 | 0 | NA | |
35 | hsa-miR-128-3p | ESCO2 | 0.78 | 0 | -1.34 | 0 | miRNAWalker2 validate | -0.41 | 0 | NA | |
36 | hsa-miR-128-3p | FAM126A | 0.78 | 0 | -0.57 | 0 | MirTarget | -0.19 | 0 | NA | |
37 | hsa-miR-128-3p | FKBP10 | 0.78 | 0 | -0.55 | 0 | miRNAWalker2 validate | -0.3 | 0 | NA | |
38 | hsa-miR-128-3p | G6PC3 | 0.78 | 0 | -0.14 | 0.00609 | miRNAWalker2 validate | -0.12 | 0 | NA | |
39 | hsa-miR-128-3p | GAPT | 0.78 | 0 | -0.59 | 0.00024 | MirTarget | -0.38 | 0 | NA | |
40 | hsa-miR-128-3p | GATA6 | 0.78 | 0 | -0.69 | 7.0E-5 | miRNAWalker2 validate; MirTarget | -0.25 | 0.00014 | NA | |
41 | hsa-miR-128-3p | GCC1 | 0.78 | 0 | -0.1 | 0.0247 | MirTarget | -0.1 | 0 | NA | |
42 | hsa-miR-128-3p | GFPT2 | 0.78 | 0 | 0.13 | 0.27512 | miRNAWalker2 validate | -0.11 | 0.00957 | NA | |
43 | hsa-miR-128-3p | GLTSCR2 | 0.78 | 0 | 0.05 | 0.48314 | miRNAWalker2 validate | -0.12 | 0 | NA | |
44 | hsa-miR-128-3p | GYS1 | 0.78 | 0 | -0.16 | 0.00181 | MirTarget | -0.13 | 0 | NA | |
45 | hsa-miR-128-3p | HIC1 | 0.78 | 0 | -0.29 | 0.00052 | MirTarget | -0.22 | 0 | NA | |
46 | hsa-miR-128-3p | HMOX1 | 0.78 | 0 | -0.44 | 2.0E-5 | miRNAWalker2 validate | -0.36 | 0 | NA | |
47 | hsa-miR-128-3p | HOXC6 | 0.78 | 0 | -1.49 | 0 | miRNAWalker2 validate | -0.7 | 0 | NA | |
48 | hsa-miR-128-3p | IL13RA1 | 0.78 | 0 | -0.23 | 0.01158 | MirTarget | -0.15 | 0 | NA | |
49 | hsa-miR-128-3p | JAG1 | 0.78 | 0 | -0.59 | 0 | MirTarget | -0.29 | 0 | NA | |
50 | hsa-miR-128-3p | KCTD14 | 0.78 | 0 | -0.29 | 0.00059 | miRNAWalker2 validate | -0.13 | 5.0E-5 | NA | |
51 | hsa-miR-128-3p | KLHDC8A | 0.78 | 0 | -0.65 | 0 | MirTarget | -0.27 | 0 | NA | |
52 | hsa-miR-128-3p | LBR | 0.78 | 0 | -0.22 | 5.0E-5 | miRNAWalker2 validate | -0.16 | 0 | NA | |
53 | hsa-miR-128-3p | LILRB5 | 0.78 | 0 | 0.48 | 0.00173 | miRNAWalker2 validate | -0.17 | 0.0031 | NA | |
54 | hsa-miR-128-3p | LMNB1 | 0.78 | 0 | -0.8 | 0 | miRNAWalker2 validate | -0.31 | 0 | NA | |
55 | hsa-miR-128-3p | LRAT | 0.78 | 0 | -0.18 | 0.28968 | MirTarget | -0.17 | 0.00919 | NA | |
56 | hsa-miR-128-3p | LRRN4CL | 0.78 | 0 | -1.13 | 0 | MirTarget | -0.45 | 0 | NA | |
57 | hsa-miR-128-3p | LTBP1 | 0.78 | 0 | -0.17 | 0.10981 | MirTarget | -0.15 | 0.0002 | NA | |
58 | hsa-miR-128-3p | MAP3K8 | 0.78 | 0 | -0.16 | 0.05637 | MirTarget | -0.14 | 1.0E-5 | NA | |
59 | hsa-miR-128-3p | MAPKAPK3 | 0.78 | 0 | -0.07 | 0.28057 | MirTarget | -0.13 | 0 | NA | |
60 | hsa-miR-128-3p | NEK2 | 0.78 | 0 | -1.47 | 0 | miRNAWalker2 validate; MirTarget | -0.29 | 0 | 24046120 | In particular we examined miR-128 expression which is thought to target NEK2; We measured NEK2 mRNA and miR-128 levels in clinical samples by quantitative reverse transcription real-time PCR and analyzed the associations between NEK2 levels miR-128 levels clinicopathological factors and prognoses; MiR-128 inhibited NEK2 expression and cancer cell proliferation via cell cycle arrest; Patients with high miR-128 expression had significantly lower NEK2 expression and lower recurrence rates than those with low miR-128 expression; NEK2 may be an independent prognostic factor for CRC and was regulated by miR-128 a microRNA that was subjected to epigenetic regulation |
61 | hsa-miR-128-3p | NFIL3 | 0.78 | 0 | -0.39 | 0 | MirTarget | -0.17 | 0 | NA | |
62 | hsa-miR-128-3p | NOP2 | 0.78 | 0 | -0.22 | 2.0E-5 | miRNAWalker2 validate | -0.17 | 0 | NA | |
63 | hsa-miR-128-3p | NXT1 | 0.78 | 0 | -0.33 | 0 | miRNAWalker2 validate | -0.25 | 0 | NA | |
64 | hsa-miR-128-3p | PDIA5 | 0.78 | 0 | -0.58 | 0 | MirTarget | -0.37 | 0 | NA | |
65 | hsa-miR-128-3p | PDPN | 0.78 | 0 | -1.01 | 0 | MirTarget | -0.47 | 0 | NA | |
66 | hsa-miR-128-3p | PHB | 0.78 | 0 | -0.1 | 0.04099 | MirTarget | -0.1 | 0 | NA | |
67 | hsa-miR-128-3p | PHC2 | 0.78 | 0 | -0.21 | 0.0006 | MirTarget | -0.15 | 0 | NA | |
68 | hsa-miR-128-3p | PPP4C | 0.78 | 0 | -0.21 | 5.0E-5 | MirTarget | -0.2 | 0 | NA | |
69 | hsa-miR-128-3p | PQLC3 | 0.78 | 0 | -0.24 | 7.0E-5 | MirTarget | -0.17 | 0 | NA | |
70 | hsa-miR-128-3p | PRKD1 | 0.78 | 0 | 0.02 | 0.6922 | MirTarget | -0.12 | 0 | NA | |
71 | hsa-miR-128-3p | PRR11 | 0.78 | 0 | -0.7 | 0 | miRNAWalker2 validate | -0.11 | 0.03256 | NA | |
72 | hsa-miR-128-3p | RAB20 | 0.78 | 0 | -0.05 | 0.56131 | MirTarget | -0.23 | 0 | NA | |
73 | hsa-miR-128-3p | RAB34 | 0.78 | 0 | -0.59 | 0 | MirTarget | -0.15 | 0.00061 | NA | |
74 | hsa-miR-128-3p | RAP1B | 0.78 | 0 | -0.14 | 0.00328 | MirTarget | -0.15 | 0 | 25017996 | miR 128 and miR 149 enhance the chemosensitivity of temozolomide by Rap1B mediated cytoskeletal remodeling in glioblastoma |
75 | hsa-miR-128-3p | RDX | 0.78 | 0 | -0.09 | 0.16153 | MirTarget | -0.12 | 0 | NA | |
76 | hsa-miR-128-3p | RPL28 | 0.78 | 0 | -0.08 | 0.27539 | miRNAWalker2 validate | -0.15 | 0 | NA | |
77 | hsa-miR-128-3p | SAMD9L | 0.78 | 0 | -0.47 | 1.0E-5 | MirTarget | -0.25 | 0 | NA | |
78 | hsa-miR-128-3p | SEC61A1 | 0.78 | 0 | -0.27 | 1.0E-5 | miRNAWalker2 validate; MirTarget | -0.18 | 0 | NA | |
79 | hsa-miR-128-3p | SFXN2 | 0.78 | 0 | 0.09 | 0.15796 | miRNAWalker2 validate | -0.12 | 0 | NA | |
80 | hsa-miR-128-3p | SKA3 | 0.78 | 0 | -1.24 | 0 | MirTarget | -0.38 | 0 | NA | |
81 | hsa-miR-128-3p | SLC16A1 | 0.78 | 0 | -0.32 | 0 | miRNAWalker2 validate | -0.15 | 0 | NA | |
82 | hsa-miR-128-3p | SLC39A7 | 0.78 | 0 | -0.17 | 0.00058 | miRNAWalker2 validate; MirTarget | -0.13 | 0 | NA | |
83 | hsa-miR-128-3p | SOX11 | 0.78 | 0 | -0.27 | 0.02742 | miRNAWalker2 validate | -0.18 | 3.0E-5 | NA | |
84 | hsa-miR-128-3p | SOX2 | 0.78 | 0 | -0.06 | 0.49975 | miRNAWalker2 validate | -0.13 | 0 | NA | |
85 | hsa-miR-128-3p | SPG21 | 0.78 | 0 | -0.06 | 0.16752 | MirTarget | -0.12 | 0 | NA | |
86 | hsa-miR-128-3p | SSFA2 | 0.78 | 0 | -0.3 | 0 | miRNAWalker2 validate | -0.11 | 0 | NA | |
87 | hsa-miR-128-3p | STEAP3 | 0.78 | 0 | -0.85 | 0 | MirTarget | -0.37 | 0 | NA | |
88 | hsa-miR-128-3p | STK3 | 0.78 | 0 | -0.16 | 0.00329 | miRNAWalker2 validate; MirTarget | -0.2 | 0 | NA | |
89 | hsa-miR-128-3p | STK40 | 0.78 | 0 | -0.43 | 0 | MirTarget | -0.21 | 0 | NA | |
90 | hsa-miR-128-3p | SUMF1 | 0.78 | 0 | -0.19 | 0.00034 | miRNAWalker2 validate | -0.12 | 0 | NA | |
91 | hsa-miR-128-3p | TAGLN | 0.78 | 0 | -0.28 | 0.00367 | miRNAWalker2 validate | -0.18 | 0 | NA | |
92 | hsa-miR-128-3p | TGFBR1 | 0.78 | 0 | -0.34 | 0 | miRNAWalker2 validate; miRTarBase | -0.21 | 0 | NA | |
93 | hsa-miR-128-3p | TIA1 | 0.78 | 0 | -0.02 | 0.7735 | MirTarget | -0.1 | 0 | NA | |
94 | hsa-miR-128-3p | TM4SF1 | 0.78 | 0 | -0.73 | 0 | miRNAWalker2 validate | -0.26 | 0 | NA | |
95 | hsa-miR-128-3p | TMEM64 | 0.78 | 0 | -0.16 | 0.00347 | MirTarget | -0.12 | 0 | NA | |
96 | hsa-miR-128-3p | TMX1 | 0.78 | 0 | -0.16 | 0.00337 | MirTarget | -0.17 | 0 | NA | |
97 | hsa-miR-128-3p | TNFAIP8 | 0.78 | 0 | -0.77 | 0 | MirTarget | -0.41 | 0 | NA | |
98 | hsa-miR-128-3p | TROVE2 | 0.78 | 0 | -0.08 | 0.09467 | miRNAWalker2 validate | -0.12 | 0 | NA | |
99 | hsa-miR-128-3p | TSPAN6 | 0.78 | 0 | -0.14 | 0.03739 | miRNAWalker2 validate | -0.19 | 0 | NA | |
100 | hsa-miR-128-3p | TXNDC5 | 0.78 | 0 | -0.35 | 0 | MirTarget | -0.15 | 0 | NA | |
101 | hsa-miR-128-3p | TXNIP | 0.78 | 0 | 0.01 | 0.92255 | miRNAWalker2 validate; MirTarget | -0.12 | 0 | NA | |
102 | hsa-miR-128-3p | UTP15 | 0.78 | 0 | -0.22 | 0 | MirTarget | -0.13 | 0 | NA | |
103 | hsa-miR-128-3p | VANGL2 | 0.78 | 0 | 0.04 | 0.60519 | MirTarget | -0.12 | 0 | NA | |
104 | hsa-miR-128-3p | VSIG10 | 0.78 | 0 | -0.06 | 0.2412 | MirTarget | -0.12 | 0 | NA | |
105 | hsa-miR-128-3p | WEE1 | 0.78 | 0 | -0.99 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.41 | 0 | NA | |
106 | hsa-miR-128-3p | ZNF552 | 0.78 | 0 | -0.22 | 0 | miRNAWalker2 validate | -0.14 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 18 | 876 | 7.534e-07 | 0.001267 |
2 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 17 | 788 | 8.167e-07 | 0.001267 |
3 | CIRCULATORY SYSTEM DEVELOPMENT | 17 | 788 | 8.167e-07 | 0.001267 |
4 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 25 | 1656 | 1.317e-06 | 0.001532 |
5 | REGULATION OF CELL CYCLE | 18 | 949 | 2.356e-06 | 0.002192 |
6 | TUBE DEVELOPMENT | 13 | 552 | 7.143e-06 | 0.005539 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | MAPK_signaling_pathway_hsa04010 | 8 | 295 | 0.000176 | 0.007149 | |
2 | TNF_signaling_pathway_hsa04668 | 5 | 108 | 0.000275 | 0.007149 | |
3 | p53_signaling_pathway_hsa04115 | 3 | 68 | 0.005649 | 0.09792 | |
4 | Cytokine_cytokine_receptor_interaction_hsa04060 | 5 | 270 | 0.01451 | 0.1887 | |
5 | Ferroptosis_hsa04216 | 2 | 40 | 0.01904 | 0.1973 | |
6 | Rap1_signaling_pathway_hsa04015 | 4 | 206 | 0.02406 | 0.1973 | |
7 | AMPK_signaling_pathway_hsa04152 | 3 | 121 | 0.02656 | 0.1973 | |
8 | FoxO_signaling_pathway_hsa04068 | 3 | 132 | 0.03315 | 0.205 | |
9 | Apoptosis_hsa04210 | 3 | 138 | 0.03707 | 0.205 | |
10 | PI3K_Akt_signaling_pathway_hsa04151 | 5 | 352 | 0.03943 | 0.205 | |
11 | Hippo_signaling_pathway_hsa04390 | 3 | 154 | 0.04864 | 0.2299 | |
12 | Adherens_junction_hsa04520 | 2 | 72 | 0.05596 | 0.2425 | |
13 | TGF_beta_signaling_pathway_hsa04350 | 2 | 84 | 0.07331 | 0.2932 | |
14 | HIF_1_signaling_pathway_hsa04066 | 2 | 100 | 0.09867 | 0.3665 | |
15 | Ras_signaling_pathway_hsa04014 | 3 | 232 | 0.1255 | 0.3911 | |
16 | Lysosome_hsa04142 | 2 | 123 | 0.1386 | 0.3911 | |
17 | Endocytosis_hsa04144 | 3 | 244 | 0.1399 | 0.3911 | |
18 | Cell_cycle_hsa04110 | 2 | 124 | 0.1404 | 0.3911 | |
19 | Apelin_signaling_pathway_hsa04371 | 2 | 137 | 0.1643 | 0.4069 | |
20 | Cellular_senescence_hsa04218 | 2 | 160 | 0.2082 | 0.4508 | |
21 | Jak_STAT_signaling_pathway_hsa04630 | 2 | 162 | 0.2121 | 0.4508 | |
22 | cAMP_signaling_pathway_hsa04024 | 2 | 198 | 0.2825 | 0.5101 | |
23 | Focal_adhesion_hsa04510 | 2 | 199 | 0.2845 | 0.5101 | |
24 | Regulation_of_actin_cytoskeleton_hsa04810 | 2 | 208 | 0.3021 | 0.5237 |